scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.LEUKRES.2003.11.002 |
P698 | PubMed publication ID | 15120936 |
P50 | author | Hagop Kantarjian | Q60394812 |
Francis J Giles | Q62066745 | ||
Maher Albitar | Q66429840 | ||
Susan M O'Brien | Q87633434 | ||
Julie M Vose | Q87934467 | ||
James O Armitage | Q87934469 | ||
Taghi Manshouri | Q91467065 | ||
Philip J Bierman | Q116794963 | ||
R Gregory Bociek | Q117253702 | ||
Marcella M Johnson | Q117253759 | ||
P2093 | author name string | Kim-Anh Do | |
P433 | issue | 6 | |
P304 | page(s) | 595-604 | |
P577 | publication date | 2004-06-01 | |
P1433 | published in | Leukemia Research | Q15716445 |
P1476 | title | Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma | |
P478 | volume | 28 |
Q46979566 | A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma. |
Q53222523 | Angiogenesis-related growth factors and cytokines in the serum of patients with B non-Hodgkin lymphoma; relation to clinical features and response to treatment. |
Q33999348 | Angiogenin: a review of the pathophysiology and potential clinical applications |
Q53221535 | Clinical correlations and prognostic relevance of HGF, VEGF AND FGF expression in Brazilian patients with non-Hodgkin lymphoma. |
Q42261011 | Clinical significance of serum hepatocyte growth factor (HGF) levels in hepatocellular carcinoma |
Q47920503 | Current status and future prospects of biomarkers in the diagnosis of hepatocellular carcinoma. |
Q30490554 | Diagnosis of hepatocellular carcinoma. |
Q64915467 | Discriminant analysis involving serum cytokine levels and prediction of the response to therapy of patients with Hodgkin lymphoma. |
Q46193990 | Does serum soluble vascular endothelial growth factor levels have different importance in pediatric acute leukemia and malignant lymphoma patients? |
Q61795626 | Hepatocyte Growth Factor: A Microenvironmental Resource for Leukemic Cell Growth |
Q36646078 | High MET gene copy number predicted poor prognosis in primary intestinal diffuse large B-cell lymphoma |
Q53173084 | Inhibition of c-MET is a potential therapeutic strategy for treatment of diffuse large B-cell lymphoma. |
Q28080705 | Lymphoma: immune evasion strategies |
Q38751343 | Microenvironmental interactions between endothelial and lymphoma cells: a role for the canonical WNT pathway in Hodgkin lymphoma. |
Q28079232 | Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies |
Q33406444 | Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma |
Q38968332 | Role of vascular endothelial growth factor C in classical Hodgkin lymphoma. |
Q53485702 | Serum VEGF as a significant marker of treatment response in hodgkin lymphoma. |
Q60340626 | Serum angiogenin levels predict treatment response in patients with stage IV melanoma |
Q45280594 | Serum vascular endothelial growth factor-a levels during induction therapy in children with acute lymphoblastic leukemia |
Q51733952 | The prognostic significance of VEGF-C and VEGF-A in non-Hodgkin lymphomas. |
Q41953798 | VEGF and bFGF gene polymorphisms in patients with non-Hodgkin's lymphoma. |
Search more.